MERT ULAŞ BARUT, Sibel SAK, Muhammet Erdal SAK

Kliniğimize Başvuran Mol Gebelik Olgularının Retrospektif İncelenmesi

Amaç: Çalışmamızda kliniğimizde parsiyel ve komplet mol hidatiform tanısı alan olguların retrospektif olarakanalizini amaçladık.Yöntemler: Bu çalışmada, Ocak 2015 - Ocak 2018 tarihleri arasında gestasyonel trofoblastik hastalık tanısı alan 89hastanın dosya bilgisine ulaşıldı ve retrospektif olarak değerlendirildi. Toplam 89 hastanın kayıtları incelendi.Hastalardan 76 komplet molar ve 13 parsiyel molar gebelik olmak üzere iki gruba ayrıldı. Mevcut kayıtlardanhastaların yaş, gravida, parite, abortus, kan grupları, β HCG, vakum küretaj öncesi ß-HCG değerleri, serum tiroiduyarıcı hormon (TSH), serbest tiroksin (T4) ve serbest tri-iyodotironin (T3) ve histopatoloji ile ilgili sonuçları kayıtedildi.Bulgular: Ocak 2015 - Ocak 2018 tarihleri arasında toplam doğum sayısı 3927 olarak tespit edildi. Gestasyoneltrofoblastik hastalık insidansı 22.6/1000 doğum olarak tespit edildi. Çalışmaya dahil edilen kadınların yaş dağılımıincelendiğinde; yaş ortalaması 29.55±9.79 olarak bulundu. Çalışmada parsiyel mol tanısı alan olguların beta HCGortalama değeri 229082±354929.69 mIU/ml, komplet mol tanısı alan olguların ise 258017.47±379942 mIU/ml olarakbulundu. Beta HCG değerleri açısından iki grup arasında istatistiksel olarak anlamlı fark bulunmadı (P=0.784).Olguların tiroid fonksiyon testleri incelendiğinde, %13,4 (12)’ünün hipertiroidi olduğu bulundu. Hastaların vakumküretajmateryallerinin histopatoloji sonuçları incelendiğinde, olguların %85,4 (76)’ ünün komplet mol iken %14,6(13)’sının parsiyel mol olduğu izlendi.Sonuç: Çalışmamızda sonuç olarak, molar gebelik vakalarında tetkik ve tedavileri göz önüne alındığında tiroidfonksiyon testi etkilendiği gözlenmektedir. Bu olgularda anestezi öncesi mutlaka tiroid fonksiyon testlerideğerlendirmek gerekir. Bu olgulara küretaj sonrasında β- hCG takiplerinin yapılması hususunda hastalarbilgilendirilmeli ve herhangi bir takip yapılmaması halinde hayati tehlike oluşturabileceği açıklanmalıdır.

Retrospective Assessment of Molar Pregnancy Cases Admitted to Our Clinic

Objective: We aimed to retrospectively analyze the cases of partial and complete hydatidiform mole in our clinic. Methods: In the present study, hospital records of 89 patients with gestational trophoblastic disease between January 2015 and January 2018 was obtained and evaluated, retrospectively. A total of 89 patients' records were examined. Patients were divided into two groups; 76 patients with complete molar and 13 patients with partial molar pregnancies. Age, gravida, parity, abortus, blood groups, β-HCG, ß-HCG values before vacuum curettage, serum thyroid stimulating hormone (TSH), free thyroxine (T4) and free triiodothyronine (T3) values, and histopathological findings of the patients were recorded from the existing records. Results: The total number of births was 3,927 between January 2015 and January 2018. The incidence of gestational trophoblastic disease was 22.6/1000 births. When the age distribution of the women included in the study was examined; the mean age was found as 29.55 ± 9.79 years. In the study, the mean values of beta HCG were 229082 ± 354929.69 mIU / ml and 258017.47±379942 mIU/ml in patients diagnosed with partial mole and complete mole, respectively. There was no statistically significant difference between the two groups in terms of beta HCG values (p = 0.784). When thyroid function tests of the cases were examined, it was found that 13.4% (12) had hyperthyroidism. In accordance with the histopathological results vacuum-curettage materials of the patients, it was observed that 85.4% (76) of the cases were complete mole and 14.6% (13) were partial mole. Conclusion: Thyroid function tests were influenced in view of examinations and treatments in molar pregnancy cases. In these cases, it is required to evaluate thyroid function tests before anesthesia. Patients should be informed about performing β-hCG follow-ups after curettage and it should be explained that if there is no follow-up, life risk may occur.

PDF

___

Zhao P, Chen Q, Lu W: Comparison of different therapeutic strategies for complete hydatidiform mole in women at least 40 years old. A retrospective cohort study. BMC cancer. 2017; 17: 733.
DiSaia PJ, Creasman WT. Gestational Trophoblastic Neoplasia. In: DiSaia PJ, CreasmanWT, eds. Clinical Gynecologic Oncology. St Louis: Mosby-Yer Book Inc.1997: 180-201.
Bracken MB, Brinton LA, Hayashi K. Epidemiology of hydatidiform mole and choriocarcinoma. Epidemiol Rev. 1984; 6: 52-75.
E. Jauniaux. Ultrasound diagnosis and follow-up of gestational trophoblastic disease Ultrasound Obstet. Gynecol. 1998; 11: 367-77.
Fowler DJ, Lindsay I, Seckl MJ, Sebire NJ. Routine preevacuation ultrasound diagnosis of hydatidiform mole: experience of more than 1000 cases from a regional referral center Ultrasound Obstet. Gynecol. 2006; 27: 56-60.
Kirk E, Papageorghiou AT, Condous G, Bottomley C, Bourne T. The accuracy of first trimester ultrasound in the diagnosis of hydatidiform mole Ultrasound Obstet. Gynecol. 2007; 29: 70-5.
Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease Lancet. 2010; 376: 717-29.
Berkowitz RS, Goldstein DP. Current advances in the management of gestational trophoblastic disease Gynecol. Oncol. 2013; 128: 3-5.
Brown J, Naumann RW, Seckl MJ, Schink J. 15 years of progress in gestational trophoblastic disease: scoring, standardization, and salvage. Gynecol Oncol.2017; 144: 200–7.
Palmer JR, Driscoll SG, Rosenberg L, Berkowitz RS, Lurain JR, Soper J. Oral contraceptive use and risk of gestational trophoblastic tumors. J Natl Cancer Inst. 1999; 91: 635- 40.
Hayashi K, Bracken MB, Freeman DH Jr, Hellenbrand K. Hydatidiform mole in the United States (1970-1977): a statistical and theoretical analysis. Am J Epidemiol. 1982; 115: 67- 77.
Matsui H, Iitsuka Y, Yamazawa K, Tanaka N, Seki K, Sekiya S. Changes in the incidence of molar pregnancies. A population based study in Chiba Prefecture and Japan between 1974 and 2000. Hum. Reprod. 2003; 18: 172- 5.
Gül T, Yılmaztürk A, Erden AC. A review of trophoblastic diseases at the medical school of Dicle university. Eur J Obstet Gynecol Reprod Biol. 1997; 74: 37- 40.
Çetin M, Balta Ö, Duran B, Güvenal T, Yanar O. Kliniğimize Başvuran Mol Gebelik Olgularının Retrospektif incelenmesi. C. Ü. Tıp Fakültesi Dergisi. 2004; 26: 18- 22.
Gül A, Çelebi H. Yüzüncü Yıl Üniversitesi Tıp Fakültesi Kadın Doğum Kliniğindeki Trofoblastik Hastalıkların Değerlendirilmesi. T Klin J Gynecol Obst. 2000; 10: 192- 5.
Lurain JR. Pharmacotherapy of gestational trophoblastic disease. Expert Opin Pharmacother. 2003; 4: 2005- 17.
Bagshwe KD, Dent J, Webb J: Hydatiform mole in United Kingdom 1973-1983. Lancet. 1986; 2: 673- 7.
Martin BH, Kim JH. Changes in gestational trophoblastic tumors over four decades. A Korean experience. The Journal of reproductive medicine. 1998; 43: 60-8.
Sebire NJ, Foskett M, Fisher RA, Rees H, Seckl M, Newlands E. Risk of partial and complete hydatidiform molar pregnancy in relation to maternal age. BJOG : an international journal of obstetrics and gynaecology. 2002; 109: 99-102.
Sand PK, Lurain JR, Brewer JI. Repeat gestational trophoblastic disease. Obstetrics and gynecology. 1984; 63: 140-4.
Tierney JP, Welsh J, Owen P. Management of early pregnancy loss--a complete audit cycle. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2006; 26: 229-32.
Braga A, Moraes V, Maestá I, Amim Júnior J, RezendeFilho Jd, Elias K, et al.: Changing trends in the clinical presentation and management of complete hydatidiform mole among Brazilian women. Int J Gynecol Cancer. 2016; 26: 984–90.
Braga A, Obeica B, Werner H, Sun SY, Júnior JA, Rezende Filho J, Júnior EA: A twin pregnancy with a hydatidiform mole and a coexisting live fetus: prenatal diagnosis, treatment, and follow-up. Journal of ultrasonography. 2017; 17: 299.
Bruce S, Sorosky J: Gestational Trophoblastic Disease. StatPearls Publishing. 2017.